key: cord-0977316-ugmsnron authors: Louis, David W.; Saad, Marwan; Vijayakumar, Shilpa; Ilyas, Suleman; Kokkirala, Aravind; Aronow, Herbert D. title: The Cardiovascular Manifestations of COVID-19 date: 2022-03-23 journal: Cardiol Clin DOI: 10.1016/j.ccl.2022.03.001 sha: c835ce84810c2470a04544f0cbd91e4479cb9d44 doc_id: 977316 cord_uid: ugmsnron The Coronavirus 2019 (COVID-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) virus, has resulted in unprecedented morbidity and mortality worldwide. While COVID-19 typically presents as viral pneumonia, cardiovascular manifestations such as acute coronary syndromes, arterial and venous thrombosis, acutely decompensated heart failure, and arrhythmia are frequently observed. Many of these complications are associated with poorer outcomes, including death. Herein we review the relationship between cardiovascular risk factors and outcomes among patients with COVID-19, cardiovascular manifestations of COVID-19, and cardiovascular complications associated with COVID-19 vaccination. The presence of myocardial injury in those with COVID-19 has also been associated with significant increase in mortality. Guo et al. observed markedly higher in-hospital adverse events including death, acute respiratory distress syndrome (ARDS), malignant arrhythmias, acute coagulopathy, and acute kidney injury in patients with elevated Tn-T levels compared to patients with normal Tn-T 9 . Shi et al. similarly found that patients with myocardial injury experienced higher rates of mortality, both from time of symptom onset and from index admission date 10 . Additionally, in a study of 179 patients with COVID-19 pneumonia, elevated troponin-I (Tn-I) was a predictor of mortality 11 . The presence of myocardial injury in patients hospitalized for COVID-19 suggests critical systemic illness, and these patients fare poorly even if the criteria for myocardial infarction are absent. Acute viral infections, such as SARS-CoV-2, are associated with activation of inflammatory, prothrombotic, and procoagulant cascades 13 , which likely play an important role in the increased risk of acute coronary syndromes through coronary plaque instability and thrombosis 13 . At the onset of the pandemic, significant reductions in hospitalizations for chest pain and ACS 14, 15 and an increased incidence of out-of-hospital cardiac arrest were noted 16 . Although uncertain, these were more common, and patients were more likely to present with cardiogenic shock 17 . While primary PCI remained the gold standard for treatment of ACS, strained hospital resources, perceived risk to catheterization lab personnel, and system delays negatively impacting door-toballoon time prompted conversations about the use of fibrinolytics for patients presenting with STEMI 18, 19 . In a large observational study evaluating in-hospital mortality in patients hospitalized with STEMI, fibrinolytics were used more frequently as reperfusion therapy in patients with COVID-19 than in patients without COVID-19 (0.2% vs 1.9%; p < 0.001), but their use was still much less common than that of primary percutaneous coronary intervention 20 . Studies have noted a variable but elevated incidence of venous thromboembolism (VTE) among patients hospitalized with COVID-19 [27] [28] [29] [30] [31] . The risk of VTE appears to be significantly higher in hospitalized than ambulatory patients with COVID-19 29 . In a meta-analysis of 48 studies with a total pooled sample of 18,093 patients, the overall pooled incidence of VTE, deep vein thrombosis (DVT) and pulmonary embolism (PE) was 17.0% (95% CI: 13.4 -20.9), 12.1% (95% CI: 8.4 -16.4%), and 7.1% (95% CI: 5.3-9.1%), respectively 32 . The incidence of VTE is significantly higher among patients cared for in the ICU compared to a medical ward (27.9% vs 7.1%) 32 . Other venous thromboses have been reported, including catheter-associated thrombosis 31 , renal replacement therapy (RRT) filter thrombosis 33 , and portal and mesenteric vein thromboses 34 . Arterial thromboembolism including acute ischemic stroke, ACS, acute limb ischemia (ALI), mesenteric, renal, and splenic infarcts have all been documented in patients with COVID-19 26, 27, 33, 35, 36 . In a study of patients with COVID-19 presenting with STEMI, those with COVID-19 were more likely to have multivessel coronary thrombosis, stent thrombosis and more likely to require adjunctive glycoprotein IIb/IIIa inhibitor agents, aspiration thrombectomy, and multivessel PCI compared to patients without COVID-19 37 . Furthermore, grade 2-3 myocardial blush suggesting improved myocardial perfusion was more common in patients without than with COVID-19 37 . An observational study from the Lombardi region of Italy noted a significant rise in cases of ALI during a three-month period compared to the prior year (16.3% vs 1.8%, p < 0.001) 38 . Notable predictors of ALI included > 50% lung involvement on CT scan, elevated Ddimer, and low fibrinogen 26 . Furthermore, in-hospital death was significantly higher in patients with COVID-19 and an acute thrombotic event than in those with COVID-19 but without a thrombotic event (40% vs 16.2%, p = 0.002); relatedly, those with both a thrombotic event and COVID-19 had a higher in-hospital mortality rate than those with a thrombotic event in the absence of concomitant COVID-19 infection (40% vs 3.1%, p < 0.001) 26 . Acute ischemic stroke secondary to large vessel occlusion has also been documented in patients hospitalized with COVID-19 36 . In a retrospective, self-controlled case series of 5,119 patients with COVID-19 in a Danish hospital, the incidence of ischemic stroke was approximately 10 times higher (incidence ratio 12.9 [95% CI: 7.1-23.5; p < 0.001)] when compared to patients during a pre-COVID-19 control time interval 36 . A higher rate of stroke has been observed in hospitalized patients with COVID-19 than influenza 39 . Importantly however, in a retrospective study of 8,163 patients, only 1.3% with symptomatic COVID-19 and 1.0% of asymptomatic J o u r n a l P r e -p r o o f COVID-19 developed an acute ischemic stroke, suggesting that while the relative risk of stroke is significantly increased, the absolute risk remains low 40 . Nonetheless, in this cohort, in-hospital mortality was significantly higher following acute ischemic stroke in those with COVID-19 than without COVID-19 (19.4% vs 6.2%, p < 0.0001%) 40 . Patients with chronic HF are particularly vulnerable to SARS-CoV-2 infection. Early in the pandemic, reductions in ED visits and hospitalizations for acute decompensated heart failure were noted 41, 42 . Despite these reductions, chronic HF remained an important risk factor for admission in patients with COVID-19 43 . In-hospital complications including death were more frequently observed in patients with underlying HF admitted for COVID-19 44 Myocarditis with or without pericardial involvement (myopericarditis) is an uncommon but welldocumented complication of viral infection, and can result in hospitalization, HF, arrhythmia, and sudden death 46 . Myocarditis has been reported secondary to influenza 47 and Middle Eastern respiratory syndrome coronavirus (MERS-CoV) 48 in previously healthy patients. Pathologic mechanisms responsible for viral myocarditis are hypothesized to include a post-viral autoimmune reaction, antigenic mimicry, and direct immune injury with cytokine storm 49, 50 . Presenting signs and symptoms of acute myocarditis are non-specific (dyspnea, chest pain, palpitations, peripheral edema, pre-syncope/syncope) and can delay diagnosis. In patients with suspected acute myocarditis, diagnostic strategies should include the assessment of cardiac biomarkers, inflammatory markers, and echocardiographic evaluation of ventricular function. There have been many reports of COVID-19-associated myocarditis since the onset of the Palpitations have been reported as the presenting symptom in 10% of patients, 57 and sinus tachycardia has been documented as the most common cardiac rhythm disturbance, likely as a physiologic compensation mechanism to acute illness 58 . An early report from China noted that 17% of their total cohort and 44% of patients requiring ICU level of care had documented arrhythmia; 4 however in a larger cohort of 700 patients admitted to a Pennsylvania hospital with COVID-19, no cases of heart block, sustained ventricular tachycardia (VT), or ventricular fibrillation (VF) were noted, and only 9 episodes of clinically significant bradyarrhythmia resulting in hypotension, 25 incidents of atrial fibrillation requiring amiodarone and diltiazem, and 10 non-sustained VT episodes were observed 59 . COVID-19, the pooled prevalence of AF was 11%. In subgroup analysis, patients > 60 years old exhibited a 2.5-fold higher prevalence, and patients with severe COVID-19 had a 6-fold higher prevalence of AF compared to younger and less critically ill patients, respectively 63 . The initial EUA of hydroxychloroquine for the treatment of COVID-19 sparked concern regarding the risk of QT prolongation and Torsade de Pointes. However subsequent studies observed modest QT/QTc prolongation, with low rates of major ventricular arrhythmia rates and no-arrhythmia-related deaths. Furthermore, in retrospective studies 64 and prospective randomized controlled trials 65 , the use of hydroxychloroquine with or without azithromycin did not improve clinical status or mortality. As a result, hydroxychloroquine has fallen out of favor. CDC COVID-19 Case Line-Level Data, 2019 US Census Analytics & Visualization Task Force and CDC CPR DEO Situational Awareness Public Health COVID-19 Vaccinations in the United States Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis Clinical Characteristics of 138 Hospitalized Patients With Novel Coronavirus-Infected Pneumonia in Wuhan, China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19 Fourth Universal Definition of Myocardial Infarction Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study Acute myocardial injury in patients hospitalized with COVID-19 infection: A review Cardiac Troponin for the Diagnosis and Risk-Stratification of Myocardial Injury in COVID-19: JACC Review Topic of the Week Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy Global effect of COVID-19 pandemic on the rate of acute coronary syndrome admissions: a comprehensive review of published literature Characteristics Associated With Out-of-Hospital Cardiac Arrests and Resuscitations During the Novel Coronavirus Disease Initial Findings From the North American Myocardial Infarction Registry Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic Reperfusion of ST-Segment-Elevation Myocardial Infarction in the COVID-19 Era Association Between COVID-19 Diagnosis and In-Hospital Mortality in Patients Hospitalized With ST-Segment Elevation Myocardial Infarction Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China Mechanisms of thrombosis and cardiovascular complications in COVID-19 COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study Clinical Characteristics of Coronavirus Disease 2019 in China Arterial Thrombotic Events in Adult Inpatients With COVID-19 Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System Incidence of venous thromboembolism in hospitalized patients with COVID-19 Incidence of 30-Day Venous Thromboembolism in Adults Tested for SARS-CoV-2 Infection in an Integrated Health Care System in Northern California Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction Acute limb ischemia in patients with COVID-19 pneumonia Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza Acute Ischemic Stroke and COVID-19 Reduced rate of hospital presentations for heart failure during the Covid-19 pandemic in Toronto, Canada Decreases in acute heart failure hospitalizations during COVID Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19 Effect of heart failure on the outcome of COVID-19 -A meta analysis and systematic review Update on Myocarditis Influenza Myocarditis and Myositis: Case Presentation and Review of the Literature Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus Pathophysiology of viral myocarditis The role of humoral immune response Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis Myocarditis associated with Covid-19 disease: A systematic review of published case reports and case series Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data -United States Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome Takotsubo Syndrome and COVID-19: Associations and Implications Stress-Induced Cardiomyopathy-Considerations for Diagnosis and Management during the COVID-19 Pandemic Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province Cardiac arrhythmias in hospitalized patients with COVID-19: A prospective observational study in the western United States COVID-19 and cardiac arrhythmias Incidence and Mortality Trends of Atrial Fibrillation/Atrial Flutter in the United States Outcomes of atrial fibrillation in patients with COVID-19 pneumonia: A systematic review and meta-analysis Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19 Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings Myocarditis after Covid-19 Vaccination in a Large Health Care Organization Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection Long-term cardiovascular outcomes of COVID-19